Identifying myocardial ischaemia in diabetics;Identification de l'ischémie myocardique chez le diabétique

Archives des Maladies du Coeur et des Vaisseaux

Volumn 97, Issue 4, 2004, Pages 338-357

  Puel, J ^a   Valensi, P ^b   Vanzetto, G ^a   Lassmann Vague, V ^b   Monin, J L ^a   Moulin, P ^b   Ziccarelli, C ^c   Mayaudon, H ^b   Ovize, M ^a   Bernard, S ^b   Van Belle, E ^a   Halimi, S ^b  

^a Societe Francaise de Cardiologie   (France)

^b Assoc Langue Francaise l'Etude D

^c Coll Natl des Cardiol Francais ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; HUMAN; REVASCULARIZATION; REVIEW; SILENT MYOCARDIAL INFARCTION; STRESS;

ADRENERGIC BETA-ANTAGONISTS; CORONARY ARTERIOSCLEROSIS; CORONARY STENOSIS; DIABETIC ANGIOPATHIES; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; RISK FACTORS;

EID: 11144357389     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. Passa Ph, Drouin P, Issa-Sayegh M et al. Coronaires et diabète. Recommandations de l'Alfédiam. Diabete Metab 1995; 21: 446-51.
2. American diabetes association. Consensus development conference on the diagnosis of coronary artery disease in people with diabetes. Diabetes Care 1998; 21: 1551-9.
3. Grundy SM, Howard B, Smith S et al. Prevention conference VI. Diabetes and cardiovascular disease. Circulation 2002; 105: 2231-9.
4. Gibbons RJ, Balady GJ, Beasley JW et al. ACC/AHA guidelines for exercise testing. J Am Coll Cardiol 1997; 30: 260-315.
5. ANAES. Recommandations pour la pratique clinique. Suivi du patient diabétique de type 2 à l'exclusion du suivi des complications. Janvier 1999. WWW.anaes.fr.
6. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998; 21 (Suppl.): S5-S19.
7. Saydah SH, Loria CM, Eberhardt MS et al. Sublinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001; 24: 447-53.
8. Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in adults. Executive summary of the third report of the National Cholesterol Educatio Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-97.
9. The European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364-76.
10. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projection. Diabetes Care 1998; 21: 1414-31.
11. Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002; 156: 714-9.
12. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care 1998; 21: 1138-45.
13. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American heart Association. Circulation 1999; 100: 1134-46.
14. American Diabetes Association. Consensus statement: role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1993; 1.6 (2 Suppl.): 72-8.
15. Melchior T, Kober L, Madsen CR et al. Accelerating impact of diabetes mellitus on mortality in the years following an acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Eur Heart J 1999; 20: 973-8.
16. Cosson E, Guimfack M, Paries J et al. Prognosis for coronary stenoses in patients with diabetes and myocardial ischemia. Diabetes Care 2003; 26: 1313-4.
17. Kip KE, Faxon DP, Detre KM et al. Coronary angioplasty in diabetic patients. The National Heart, Lung and Blood Institute percutaneous transluminal coronary angioplasty registry. Circulation 1996; 94: 181-25.
18. Chen J, Radfort MJ, Wang Y, Krumholz HM. Care and outcome of elderly patients with acute myocardial infarction by physician speciality: the effects of comorbidity and functional limitations. Am J Med 2000; 108: 460-9.
19. Tauber G, Winkelmann BR, Schleifer T et al. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3 266 patients sheduled for coronary angiography. Am Heart J 2003; 145: 285-9.
20. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-8.
21. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-years cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-44.
22. Haffner SM, Lehto S, Rönnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
23. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohart study. BMJ 2002; 324: 939-42.
24. Becker A, Bos G, de Vegt F et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. Eur Heart J 2003; 24: 1406-13.
25. Vlietstra RE, Kronmal RA, Lie JT et al. Factors affecting the extend and severity of coronary artery disease in patients enrolled in the coronary artery surgery study. Atherosclerosis 1982; 2: 208-15.
26. Goraya TY, Leibsan CL, Palumbo PJ et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 2002; 40: 946-53.
27. Williams SB, Cusco JA, Roddy MA et al. Impaired nitric oxide-mediated vasodilatation in no-insulin-dependent diabetes. J Am Coll Cardiol 1996; 27: 567-74.
28. Knobler H, Savion N, Shenkman et al. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Throm Res 1998; 90: 181-90.
29. Sobel BE, Woodcock-Mitchell J, Schneider DJ et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetes compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistance. Circulation 1998; 97: 2213-21.
30. Nitenberg A, Lédoux S, Valensi P et al. Impairment of coronary microvascular dilatation in response to pressor-induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. Diabetes 2001; 50: 1180-5.
31. Maser RE, Mitchell BD, Vinik AI et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26: 1895-901.
32. Cohn PF. Should silent ischemia be treated in asymptomatic individuals? Circulation 1990; 82 (Suppl. II): 149-54.
33. Koïstinen MJ. Prevalence of asymptomatic myocardial ischemia in diabetics subjects. BMJ 1990; 301: 92-5.
34. Langer A, Freeman MR, Josse RG et al. Detection of myocardial ischemia in diabetes mellitus. Am J Cardiol 1991; 67: 1073-8.
35. Milan study on atherosclerosis and diabetes (MiSAD) group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risks factors in noninsulin-dependent diabetes mellitus. Am J Cardiol 1997; 79: 134-9.
36. Valensi P, Sachs RN, Lormeau B et al. Silent myocardial ischemia and left ventricular hypertrophy in diabetic patients. Diabetes Metab 1997; 23: 409-16.
37. Janand-Delenne B, Savin B, Habib G et al. Silent myocardial ischemia in patients with diabetes. Who to screen. Diabetes Care 1999; 22: 1396-400.
38. Weiner DA, Ryan TJ, Parsons L et al. Significance of silent myocardial ischemia during exercise testing in patients with diabetes mellitus. A report from coronary artery surgery study (CASS) registry. Am J Cardiol 1991; 68: 729-34.
39. Valensi P, Sachs RN, Harfouche B et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001; 24: 339-43.
40. Valensi P. Predictive value of silent myocardial ischemia in diabetic patients. Influence of age. Diabetologia 2000; 43 (Supp. 1.): A61.
41. Vanzetto G, Halimi S, Hammoud T et al. Prediction of cardiovascular events clinically selected high-risk NIDDM patients. Diabetes Care 1999; 22: 19-26.
42. Janand-Delenne B, Labastie N, Savin B et al. Poor prognosis of silent myocardial ischemia: a two years follow-up of 203 diabetic patient. Diabetologia 2000; 43 [Suppl. 1.L).
43. Mark DB, Nelson CL, Califf R et al. Continuing evolution of therapy for coronary artery disease. Initial results from era of coronary angioplasty. Circulation 1994; 89: 2015-25.
44. Mock MB, Rinqvist I, Fischer L et al. Survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1982; 66: 562-8.
45. Murphy ML, Hultgren HN, Detre K et al. Treatment of chronic stable angina. A preliminary report of survival data of the randomized Veterans Administration Cooperative Study. N Engl J Med 1977; 297: 621-7.
46. Fuster V, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50; 310-8.
47. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
48. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-72.
49. Davies MJ. The composition of coronay artery plaque. N Engl J Med 1997; 336: 1312-3.
50. Little WC, Constantinescu M, Robert J et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mil-to-moderate coronary artery disease? Circulation 1988; 78: 1157-66.
51. Ojio S, Takatsu H, Tanaka T et al. Considerable time from the onset of plaque rupture and/or thrombi until the onset of acute myocardial infarction in humans. Circulation 2000; 102: 2063-9.
52. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002; 105: 939-43.
53. Rioufol G, Finet G, Ginon I et al. Multiple atherosclerotic plaque rupture in acute coronary syndroms; a three-vessels intravascular ultrasound study. Circulation 2002; 106: 804-8.
54. Knatterud GL, Bourassa MG, Pepine CJ et al. Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study. J Am Coll Cardiol 1994; 24: 11-20. Erratum in: J Am Coll Cardiol 1995; 26: 842.
55. Knatterud GL, Bourassa MG, Pepine CJ et al. Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study. J Am Coll Cardiol 1994; 24: 11-20. Erratum in: J Am Coll Cardiol 1995; 26: 842.
56. Jonas M, Reicher-Reiss H, Boyko V et al. Usefulnes of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996; 77: 1273-7.
57. Kjekshus J, Gilpin E, Cali G and al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990; 1143-50.
58. Pyörälä K, persen TR, Kjeksus J et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coroonary artery disease: subgroup analysis of the Scandinavian simvastatin survival study. Diabetes Care 1997; 20: 614-20.
59. Sacks FM, Tonkin AM, Craven T et al. Coronary heart disease in patients with mow LDL-Clolesterol. Benefit of pravastatin in diabetics and henhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105: 1424-8.
60. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol - lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled study. Lancet 2003; 361: 2005-16.
61. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
62. Conroy RM, Piörälä K, Filzgerald AP et al. Estimation of ten-years risk of fatal cardiovascular disease in Europe: the SCORE Project. Eur Heart J 2003; 24: 897-1003.
63. UK Prospective Diabetes Study (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. (Erratum BMJ 1999; 318: 29.)
64. UK Prospective Diabetes Study (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. (Erratum BMJ 1999; 318: 29.)
65. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62
66. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint committee on prevention, detection, evaluation and treatment of high blood pressure. JNC 7 report. Jama 2003; 289: 2560-72
67. American Diabetes Association. Standards of medical care for patients with diabetes mellitus (Position statement). Diabetes Care 1998 (Suppl. 1): S23-S31.
68. Zuanetti G, Latini R, Maggioni AP et al. Effetc of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Circulation 1997; 96: 4239-45.
69. Heart outcomes prevention evaluation (HOPE) study investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
70. st, 2003.
71. Antiplatelet trialist's collaboration. Collaborative overwiev of randomized trails of antiplatelet therapy I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 71-2; 81-106.
72. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1992; 268: 1292-300.
73. Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel versus aspirin in ptients with diabetes mellitus. Am J Cardiol 2002; 90: 625-7.
74. Malmberg K, Ryden L, Eferdic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetes patients with acute myocardial infarction (DIGAMI Study); effect on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
75. Turner RC, Millns H, Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-8.
76. Okin PM, Prineas RJ, Grandits G et al. Heart rate adjustement of exercise-induced ST-segment depression identifies men who benefit from a risk factor reduction program. Circulation 1997; 96: 2899-904.
77. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
78. Yusuf S, Zucher D, Peduzzi P et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the coronary artery bypass trialist collaboration. Lancet 1994; 344: 1116-21.
79. Blumenthal RS, Cohn G, Schulman S. Medical therapy versus coronary angioplasty in stable coronary artery disease. A critical review of the literature. J Am Coll Cardiol 2000; 36: 668-73.
80. Rogers WJ, Bourassa MG, Andrews TC et al. Asymptomatic cardiac ischemia pilot (ACIP) study: Outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularisation. J Am Coll Cardiol 1995; 26: 594-605.
81. Mak K, Faxon DP. Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur Heart J 2003; 24: 1087-103.
82. BARI investigators. Seven-years outcome in the Bypass Angioplasty revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000; 35: 1122-9.
83. Abizaid A, Costa MA, Centemero M et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Insight from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001; 104: 533-8.
84. Feit F, Brooks MM, Sopko G et al. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry. Circulation 2000; 101: 2795-802.
85. Van Belle E, Abolmaali K, Bauters C et al. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J Am Coll Cardiol 1999; 34: 476-85.
86. Elezi S, Kastrati A, Pache J et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-73.
87. Van Belle E, Bauters C, Hubert E et al. Restenosis rate in diabetic patients. A comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997; 96: 1454-60.
88. Marso SP, Lincoff AM, Ellis SG et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic substudy. Circulation 1999; 100: 2477-84.
89. Bhatt DL, Marso SP, Lincoff AM et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000; 15: 922-8.
90. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-8.
91. Moses JW, Leon MB, Popma JL et al. Sirolimus-eluting stent versus standard stent in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
92. Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA); a randomised controlled trial. Lancet 2003; 361: 1149-58.
93. Inoguchi T, Yamashita T, Umeda F et al. High Incidence of silent myocardial ischemia in elderly patients with non insulin-dependent diabetes mellitus. Diabetes Res clin Pract 2000; 47: 37-44.
94. Becker A, Bos G, de Vegt F et al. Cardiovascular events in type 2 diabetes: comparison with non-diabetic individuals without and with prior cardiovascular disease. Eur Heart J 2003; 24: 1406-13.
95. Hu FB, Stampfer MJ, Solomon CG et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001; 161: 1717-23.
96. Faglia E, Favales F, Calia P et al. Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from Milan Study on atherosclerosis and diabetes (MiSAD). Diabetes Care 2002; 25: 2032-6.
97. Cho E, Rimm EB, Stampfer MJ et al. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol 2002; 40: 954-60.
98. Detournay B, Vauzelle-Kervroedan F, Charles MA et al. Epidemiology, management and costs of type 2 diabetes in France in 1998. Diabetes Metab 1999; 25: 356-65.
99. Myers RH, Kiely DK, Cupples LA et al. Parental history is an independent risk factor for coronary artery disease. The Framingham study. Am Heart J 1990; 120: 963-9.
100. Wilson PW, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
101. Gibbons RJ, Balady GJ, Bricker JT et al. ACC/AHA 2002. Guideline update for exercise testing. Summary article. A report of American College of Cardiology/American Heart Association task force on practice guidelines (Committee to update the 1997 exercise testing guidelines). Circulation 2002; 106: 1883-92.
102. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-6.
103. Nesto RW, Watson FS, Kowalchuk GJ et al. Silent myocardial ischemia and infarction in diabetics with peripheral vascular disease: assessment by dipyridamole thallium-201 scintigraphy. Am Heart J 1990; 120: 1073-7.
104. Darbar D, Gillespie N, Main G et al. Prediction of late cardiac events by dipyridamole thallium scintigraphy in patients with intermittent claudication and occult coronary artery disease. Am J Cardiol 1996; 78: 736-40.
105. Kuller LH, Velentgas P, Barzilay J et al. Diabetes mellitus. Subclinical cardiovascular disease and risk of incident of cardiovascular disease and all-cause mortality. Arterioscler Thromb Vasc Biol 2000; 20: 823-9.
106. Ponsonnaille J, Fabry R, Chapou M et al. Silent ischemic heart diseases in patients with peripheral arterial diseases. Screening and 5-year prognosis in a population of 418 patients. Arch Mal Cœur 1991; 84: 1407-11.
107. Dinneen SF, Gerstein HC. The association of microabuminuria and mortlity in non-insulin-dependant diabetes mellitus: a systematic overwiev of the literature. Arch Intern Med 1997; 157: 1413-8.
108. Rutter MK, Wahid ST, McComb JM et al. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J Am Coll Cardiol 2002; 40: 56-61.
109. Cruickshank K, Riste L, Anderson SG et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intoleronce. An integrated index of vascular function? Circulation 2002; 106: 2085-90.
110. O'Leary DH, Joseph F, Polak JF et al. For the cardiovascular health study collaborative group. Carotid artery intima media thickness as a risk factor for myocardial infarction and strocke in older adults. N Engl J Med 1999; 340: 14-22.
111. Ridker PM, Buring JE, Cook NR et al. C-Reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-7.
112. Maser Re, Mitchell BD, Vinik AI et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26: 1895-901.
113. Hosoi M, Sato T, Yamagami K et al. Impact of diabetes on coronary stenosis and coronary artery calcification detected by electron-beam computed tomography in symptomatic patients. Diabetes Care 2002; 25: 696-701.
114. Paillole C, Ruiz J, Juliard JM et al. Non-invasive identification of severe coronary artery disease in patients with long-standing diabetes mellitus. Eur J Med 1992; 1: 464-8.
115. Sheidt-Nave C, Barrett-Connor E, Wingard DL. Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population. Circulation 1990; 81: 899-906.
116. Kannel WB, Gordon T, Castelli WP. Electrocardiographic left ventricular hupertrophy and risk of coronary heart disease. The Framingham Study. Ann Intern-Med 1970; 72: 813-22.
117. Paillole C, Ruiz J, Juliard JM et al. Detection of coronary artery disease in diabetic patients. Diabetologia 1995; 38: 726-31.
118. Rubler S, Gerber D, Reitano J et al. Predictive value of clinical and exercise variable for detection of coronary artery disease in men with diabetes mellitus. Am J Cardiol 1987; 59: 1310-3.
119. Gerson MC, Khoury JC, Hertzberg VS, Fischer EE, Scott RC al. Prediction of coronary artery disease in a population of insulin-requiring diabetic patients: results of an 8-year follow-up study. Am Heart J 1988; 116: 820-6.
120. Koistinen MJ, Huikuri HV, Pirttiaho H et al. Evaluation of exercise electrocardiography and thallium tomographic imaging in detecting asymptomatic coronary artery disease in diabetic patient. Br Heart J 1990; 63: 7-11.
121. Cosson E, Paycha F, Paries J et al. Selecting silent coronary stenosis with stratifying cardiac risk in patients with diabetes. ECG stress test of exercise myocardial scintigraphy. Diabet Metab (in press).
122. Vanzetto G, Halimi S, Hammod T et al. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Diabetes Care 1999; 22: 19-26.
123. Boudreau RJ, Strony JT, du Cret RP et al. Perfusion thallium imaging of type 1 diabetes with end stage renal disease: comparison of oral and intravenous dipyridamole administration. Radiology 1990; 175: 103-5.
124. Kumar R, Patel CD, Marwah A et al. Dtection of coronary artery disease by stress thallium scintigraphy in diabetic patients. Nucl Med Commun 2001; 22: 287-9.
125. Machecourt J, Longere P, Fagret D et al. Prognostic value of thallium-201 single-photon emission computed tomographic myocardial perfusion imaging according to extent of myocardial defect. J Am Coll Cardiol 1994; 23: 1096-106.
126. Vanzetto G, Ormezzano O, Fagret D, Comet M, Denis B, Machecourt J. Long-term additive prognostic value of thallium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients: study in 1137 patients with 6-year follow-up. Circulation 1999; 100: 1521-7.
127. Hachamovitch R, Hayes S, Friedmann JD et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans. Circulation 2003; 41: 1329-40.
128. Kang X, Berman DS, Lewin HC et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. Am Heart J 1999; 138: 1025-32.
129. Faglia E, Favales F, Calia P et al. Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). Diabetes Care 2002; 25: 2032-6
130. De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion SPECT in asympyomatic patients with diabetes mellitus and no known coronary artery disease. Am J Cardiol 2002; 90: 827-32
131. Vanzetto G, Halimi S, Hammoud T et al. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomoqraphy. Diabetes Care 1999; 22: 19-26.
132. Giri S, Shaw LJ, Murthy DR. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation 2002; 105: 32-40.
133. Takeishi Y, Chiba J, Abe S et al. Noninvasive indentification of left main and three-vessel corona artery by thallium-201 photon emission computed tomography during adenosine infusion. Ann Nucl Med 1994; 8: 1-7.
134. Romanens M, Gradel C, Saner H et al. Comparison of 99mTc-sestamibi lung/heart ratio, transient of ischaemic dilation and perfusion defect size for the identification of severe and extensive coronary heart disease. Eur J Nucl Med 2001; 28: 907-10.
135. Williams KA, Schneider CM. Increased stress right ventricular activity on dual isotope perfusion SPECT: a sign of multivessel and/or left main coronary artery disease. J Am Coll Cardiol 1999; 34: 420-7.
136. Lebtahi NE, Stauffer JC, Delaloye AB. Left bundle branch block and coronary artery disease: accuracy of dipyridamole thallium-201 single-photon emission computed tomography in patients with exercise anteroseptal perfusion defects. J Nucl Cardial 1997; 4: 266-73.
137. Tandogan I, Yetkin E, Yanik A et al. Comparison of thallium-201 exercise SPECT and dobutamine stress echocardiography for diagnosis of coronary artery disease in patients with bundle branch block. Int J Cardiovasc Imaging 2001; 17: 339-45.
138. Elhendy A van Domburg RT, Poldermans D et al. Safety and feasibility of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in diabetic patients unable to perform an exercise stress test. Diabetes Care 1998; 21: 1797-802.
139. Sozzi FB, Elhendy A, Roelandt JR et al. Prognostic value of dobutamine stress echocardiography in patients with diabetes. Diabetes Care 2003; 26: 1074-8.
140. Elhendy A, Arruda AM, Mahoney DW. Pronostic stratification of diabetic patient by exercise echocardiography. J Am Coll Cardiol 2001; 37: 1551-7.
141. Shaw U, Hachamovitch R, Berman DS et al. The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia. Economics of Noninvasive Diagnosis (END) Multicenter Study. J Am Coll Cardiol 1999; 33: 661-9.
142. Gibbons RJ, Chatterjee K, Daley J et al. ACC/AHA/ACP-ASIM guide lines for the management of patients with chronic stable angina: a report from the American College of cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 1999; 33: 2092-197. (Erratum in: J Am Coll Cardiol 1999; 34: 314).
143. Gibbons RJ, Chatterjee K, Daley J et al. ACC/AHA/ACP-ASIM guide lines for the management of patients with chronic stable angina: a report from the American College of cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 1999; 33: 2092-197. (Erratum in: J Am Coll Cardiol 1999; 34: 314).
144. Schinkel AF, Bax JJ, Geleijnse ML et al. Noninvasive evaluation or ischaemic heart disease: myocardial perfusion imaging or stress echocardiography. Eur Heart J 2003; 24: 789-800.
145. Delahaye F, Bory M, Cohen A et al. Recommandations de la Société française de cardiologie concernant la prise en charge de l'infarctus du myocarde après la phase aiguë. Arch Mal Cœur 2001; 94: 697-725.